Spontaneously Occurring Tumors of Companion Animals as Models for Human Cancer

References

• MacEwen E G. Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Rev 1990; 9: 125–136
   PubMed Web of Science ®Google Scholar
• Branson R T. Variation in age at death of dogs of different sexes and breeds. Am J Vet Res 1982; 43: 2057–2059
   PubMed Web of Science ®Google Scholar
• Dorn C R. Epidemiology of canine and feline tumors. Comp Cont Educ Pract Vet 1976; 12: 307–312
   Google Scholar
• Dorn C R. Survey of animal neoplasms in alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County. L J Natl Cancer Inst 1968; 40: 307–318
   PubMed Web of Science ®Google Scholar
• Priester W A, McKay A. FW. the Occurrence of Tumors in Domestic Animals. Natl Cancer Inst Monogr No. 54, US Govt Printing Office, Washingron DC 1980; 152
   Google Scholar
• Teclaw R., Mendlein J., Garbe P, et al. Characteristics of pet populations and households in the Purdue Comparative Oncology Program catchment area, 1988. J Am Vet Med Assoc 1992; 201: 1725–1729
   PubMed Web of Science ®Google Scholar
• La Rue S M, Fox M H, Withrow S J, et al. Impact of heterogeneity in the predictive value of kinetic parameters in canine osteosarcoma. Cancer Res 1994; 54: 3916–3921
   PubMed Web of Science ®Google Scholar
• Vail D M, Kisseberth W C, Obradovich J E, et al. Assessment of potential doubling time (Tpot), argyrophilic nucleolar organizing regions (AgNOR) and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non-Hodgkin's lymphoma. Exp Hematol 1996; 24: 807–815
   PubMed Web of Science ®Google Scholar
• Zeman E M, Calkins D P, Cline J M, et al. The relationship between proliferative and oxygenation status in spontaneous canine tumors. In J Radial Oncol Biol Phys 1993; 27: 891–898
   PubMed Web of Science ®Google Scholar
• Crow S E. Lymphosarcoma in the dog: diagnosis and treatment. Comp Cont Educ Pract Vet 1982; 4: 283–289
   Google Scholar
• Rosenthal R C. Epidemiology of canine lymphosarcoma. Comp Cont Educ Pract Vet 1982; 4: 855–859
   Web of Science ®Google Scholar
• Leifer C E, Matus R E. Canine lymphoma: clinical considerations. Semin Vet Med Surg 1986; 1: 43–51
   PubMedGoogle Scholar
• Hayes H M, Tarone R E, Cantor K P, et al. Case-control study of canine malignant lymphoma: positive association with dog owner's use of 2,4-dichlorophenoxyacetic acid herbicides. JNCI 1991; 83: 1226–1231
   PubMed Web of Science ®Google Scholar
• Zahm S., Blair H. A. Pesticides and non-Hodgkin's lymphoma. Cancer Res (Suppl.) 1992; 52: 5485s–5488s
   PubMed Web of Science ®Google Scholar
• Reif J S, Lower K S, Ogilvie G K. Residential exposure to magnetic fields and risk of canine lymphoma. Am J Epidemiol 1995; 141: 352–359
   PubMed Web of Science ®Google Scholar
• World Health Organization TNM Classification of Tumors in Domestic Animals. 1st. ed, L. N. Owen. WHO, Geneva 1980
   Google Scholar
• The non-Hodgkin's lymphoma pathologic classification project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a Working Formulation for Clinical Usage. Cancer 1982; 49: 2112
   PubMed Web of Science ®Google Scholar
• Greenllee P., Filippa G. D, Quimby A. FW., et al. Lymphomas in dogs. Cancer 1990; 66: 480–490
   PubMed Web of Science ®Google Scholar
• Teske E, Rutteman G R, Kuipers-Dijkshoorn N J, et al. DNA ploidy and cell kinetics in canine non-Hodgkin's lymphoma. Exp Hematol 1993; 21: 579–584
   PubMed Web of Science ®Google Scholar
• Carter R F, Harris C K, Withrow S J, et al. Chemotherapy of canine lymphoma with histopathological correlation: doxorubicin alone compared to COP as first treatment regimen. J Am Anim Hosp Assoc 1987; 23: 587–596
   Web of Science ®Google Scholar
• Hahn K A, Richardson R. C., Hahn E A, et al. Diagnostic and prognostic importance of chromosomal aberrations identified in 61 dogs with lymphosarcoma. Vet Pathol 1994; 31: 528–540
   PubMed Web of Science ®Google Scholar
• Keller E T, MacEwen E., Rosenthal G. RC., et al. Evaluation of prognostic factors and sequential combination chemotherapy for canine lymphoma. J Am Vet Med Assoc 1992; 7: 289–295
   Google Scholar
• Moore A S, Leveille C. R., Reimann K A, et al. The expression of P-glycoprotein in canine lymphoma and its association with rnultidrug resistance. Cancer Invest 1995; 13: 475–479
   PubMed Web of Science ®Google Scholar
• Bergman P J, Ogilvie G. K., Powers B E. Monoclonal antibody C219 immunohistochemistry against P-glycoprotein: sequential analysis and predictive ability in dogs with lymphoma. J Vet Intern Med 1996; 10: 354–359
   PubMed Web of Science ®Google Scholar
• Lee J J, Hughes C S, Fine R. L., et al. P-glycoprotein expression in canine lymphoma. Cancer 1996; 77: 1892–1898
   PubMed Web of Science ®Google Scholar
• Gamblin R M, Sagartz J E, Couto C G. Overexpression of p53 tumor suppressor protein in spontaneously arising neoplasms of dogs. Am J Vet Res 1997; 58: 857–863
   PubMed Web of Science ®Google Scholar
• Brons P PT, Raemaekers J MM, Bogman M JJT, et al. Cell cycle kinetics in malignant lymphoma studied with in vivo iodeoxyuridin administration, nuclear Ki-67 staining, and flow cytometry. Blood 1992; 80: 2336–2343
   PubMed Web of Science ®Google Scholar
• Mikou P, Kanavaros P, Aninos D, et al. Nucleolar organizer regions (NORs) staining and proliferating cell nuclear antigen (PCNA) immunostaining in mucosa-associated lymphoid tissue (MALT) gastric lymphomas. Path Res Pract 1993; 189: 1004–1009
   PubMed Web of Science ®Google Scholar
• Jakic-Razumovic Tentor J. D., Petrovecki M., et al. Nucleolar organiser regions and survival in patients with non-Hodgkin's lymphomas classified by the working formulation. J Clin Pathol 1993; 46: 943–947
   PubMed Web of Science ®Google Scholar
• Crocker J, Nar P. Nucleolar organizer regions in lymphomas. J Pathol 1987; 151: 111–118
   PubMed Web of Science ®Google Scholar
• Crocker J, Macartney J C, Smith P J. Correlation between DNA flow cytometric and nucleolar organizer region data in non-Hodgkin's lymphomas. J Pathol 1988; 154: 151–156
   PubMed Web of Science ®Google Scholar
• Gorczyca W, Kram A, Tuziak T, et al. Proliferating cell nuclear antigen in archimal surgical specimens of malignant lymphoma and metastatic carcinoma: immunohistochemical and flow cytometric analysis. Patol Pol 1993; 44: 121–128
   PubMedGoogle Scholar
• Korkolopoulou P, Kittas J., Gates C., et al. p53. c-myc p62 and proliferating cell nuclear antigen (PCNA) expression in non-Hodgkin's lymphomas. J Clin Pathol 1994; 47: 9–14
   PubMed Web of Science ®Google Scholar
• Pich A, Valente R., Ponti G., et al. MIB-1, Ki-67, and PCNA scores and DNA flow cytometry in intermediate grade malignant lymphomas. J Clin Pathol 1994; 47: 18–22
   PubMed Web of Science ®Google Scholar
• Brick J O, Roenigk W J, Wilson G P. Chemotherapy of malignant lymphoma in dogs and cats. J Am Vet Med Assoc 1968; 153: 47–52
   PubMed Web of Science ®Google Scholar
• Vail D M. Recent advances in chemotherapy for lymphoma of dogs and cats. Compend Cont Educ Pract Vet 1993; 15: 1031–1037
   Web of Science ®Google Scholar
• Vail D M, Kravis L D, Cooley A J, et al. Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors. Cancer Chemother Pharmacol 1997; 39: 410–416
   PubMed Web of Science ®Google Scholar
• Vail D M, Chun R, Thamm D H, et al. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (stealth) liposomes: a randomized, doubleblind clinical trial using a canine model. Clin Cancer Res 1998; 4: 1567–1571
   PubMed Web of Science ®Google Scholar
• Cline J M, Thrall D E, Rosner G L, et al. Distribution of the hypoxic marker CCI-103F in canine tumors. Int J Radial Oncol Biol Phys 1994; 28: 921–933
   Web of Science ®Google Scholar
• Page R JL, Macy D W, Ogilvie G K, et al. Phase III evaluation of doxorubicin and whole-body hyperthermia in dogs with lymphoma. Int J Hyperthermia 1992; 8: 187–197
   PubMed Web of Science ®Google Scholar
• Applebaum F R, Deeg H J, Storb R, et al. Marrow transplant studies in dogs with malignant lymphoma. Transplantation 1985; 39: 499–504
   PubMed Web of Science ®Google Scholar
• Weiden P L, Storb R, Deeg H J, et al. Prolonged disease-free survival in dogs with lymphoma after total-body irradiation and autologous marrow translantation consolidation of combination chemotherapy -induced remissions. Blood 1979; 54: 1039–1049
   PubMed Web of Science ®Google Scholar
• Hardy W. D, Jr. The feline leukemia virus. J Am Anim Hosp Assoc 1981; 17: 951–957
   Web of Science ®Google Scholar
• Cockerell G L, Krakowka S, Hoover E A, et al. Characterization of feline T- and B-lymphocytes and identification of an experimentally induced T-cell neoplasm in the cat. J Natl Cancer Inst 1976; 57: 907–913
   PubMed Web of Science ®Google Scholar
• Hardy W. D, Jr, Zuckerman E E, MacEwen E G, et al. A feline leukemia and sarcoma virus-induced tumor specific antigen. Nature 1977; 270: 249–251
   PubMed Web of Science ®Google Scholar
• Hardy W. D, Jr, McClelland A J, Zuckerman E E, et al. Development of virus nonproducer lymphosarcomas in pet cats exposed to FeLV. Nature 1980; 288: 90
   PubMed Web of Science ®Google Scholar
• Rojko J L, Kociba G J, Abkowitz J L, et al. Feline lymphomas: Immunological and cytochemical characterization. Cancer Res 1989; 49: 345–351
   PubMed Web of Science ®Google Scholar
• Vail D M, Moore A S, Ogilvie G K, et al. Feline lymphoma (145cases): proliferation indices, CD3 immunoreactivity and their association with prognosis in 90 cats receiving therapy. J Vet Intern Med 1998; 12: 349–354
   PubMed Web of Science ®Google Scholar
• Valli V E, Norris A, Withrow S. Anatomical and histological classification of feline lymphoma using the NCI Working Formulation. Proceedings of the the 9th Annual Conference of the VCS, Raleigh, NC, October, 1989. Vol. 9, (suppl)
   Google Scholar
• Mooney S C, Hayes A A, MacEwen E G, et al. Treatment and prognostic factors in lymphoma in cats: 103 cases (1977–1981). J Am Vet Med Assoc 1989; 194: 696–702
   PubMed Web of Science ®Google Scholar
• Theilen G H, Madewell B R. Tumors of the skin and subcutaneous tissues. Veterinary Cancer Medicine, G H Theilen, B R Madewell. Lea & Febiger, Philadelphia 1979; 123–191
   Google Scholar
• Hendrick M J, Goldschmidt M H, Shofer F S, et al. Postvaccinal sarcomas in the cat: epidemiology and electron probe microanalytical identification of aluminum. Cancer Res 1992; 52: 5391–5394
   PubMed Web of Science ®Google Scholar
• Kass P H, Barnes W G, Spangler W L, et al. Epidemiologic evidence for a causal relationship between vaccination and fibrosarcoma tumorigenesis in cats. J Am Vet Med Assoc 1993; 203: 369–405
   Google Scholar
• Hendrick M J, Kass P H, McGill L D, et al. Postvaccinal sarcomas in cats. J Natl Cancer Inst 1994; 86: 341–343
   PubMed Web of Science ®Google Scholar
• Coyne M J, Reeves N C, Rosen D K. Estimated prevalence of injection-site sarcomas in cats during 1992. J Am Vet Med Assoc 1997; 210: 249–251
   PubMed Web of Science ®Google Scholar
• Hardy W. D, Jr. The etiology of canine and feline tumors. J Am Anim Hosp Assoc 1976; 12: 313–334
   Google Scholar
• Madewell B R, Theilen G H. Etiology of cancer in animals. Veterinary Cancer Medicine 2nd ed., B R Madewell, G H Theilen. Lea & Febiger, Philadelphia 1979; 13–25
   Google Scholar
• Forrest L J, Chun R, Adams W M, Cooley A J, Vail D M. Postoperative radiotherapy for canine soft tissue sarcoma. Vet Rad, (in press)
   Google Scholar
• McKnight J A, Mauldin G N, McEntee M C, et al. Radiation treatment for incompletely resected soft-tissue sarcomas in dogs. J Am Vet Med Assoc 2000; 217: 205–210
   PubMed Web of Science ®Google Scholar
• McChesney S L, Withrow S J, Gillette E L, et al. Radiotherapy of soft tissue sarcomas in dogs. J Am Vet Med Assoc 1989; 194: 60–63
   PubMed Web of Science ®Google Scholar
• Prescott D M, Charles H C, Sostman H D, et al. Manipulation of intra- and extracellular pH in spontaneous canine tumours by use of hyperglycaemia. Int J Hyperthermia 1993; 9: 745–754
   PubMed Web of Science ®Google Scholar
• Gillette S M, Dewhirst M W, Gillette E L, et al. Response of canine soft tissue sarcomas to radiation or radiation plus hyperthermia: a randomized phase II study. Int J Hyperthermia 1992; 8: 309–329
   PubMed Web of Science ®Google Scholar
• Thrall D E, Dewhirst M W, Page R L, et al. A comparison of temperatures in canine solid tumors during local and whole-body hyperthermia administered alone and simultaneously. Int J Hyperthermia 1990; 6: 305–317
   PubMed Web of Science ®Google Scholar
• Prescott D M, Samulski T V, Dewhirst M W, et al. Use of nitroprusside to increase tissue temperature during local hyperthermia in normal and tumor-bearing dogs. Int J Radial Oncol Biol Phys 1992; 23: 377–385
   Web of Science ®Google Scholar
• Dewhirst M W, Prescott D M, Clegg S, et al. The use of hydralazine to manipulate tumor temperatures during hyperthermia. Int J Hyperthermia 1990; 6: 971–983
   PubMed Web of Science ®Google Scholar
• Thrall D E, Prescott D M, Samulski T V, et al. Radiation plus local hyperthermia versus radiation plus the combination of local and whole-body hyperthermia in canine sarcomas. Int J Radiat Oncol Biol Phys 1996; 34: 1087–1096
   PubMed Web of Science ®Google Scholar
• Page R L, Thrall D E, George S L, et al. Quantitative estimation of the thermal dose-modifying factor for cis- diamminedichloro-platinum (CDDP) in tumor-bearing dogs. Int J Hyperthermia 1992; 8: 761–769
   PubMed Web of Science ®Google Scholar
• Thrall D E, McEntee M C, Cline J M, et al. ELISA quantification of CCI-103F binding in canine tumors prior to and during irradiation. Int J Radiat Oncol Biol Phys 1994; 28: 649–659
   PubMed Web of Science ®Google Scholar
• Cline J M, Thrall D E, Page R L, et al. Immunohistochemical detection of a hypoxia marker in spontaneous canine tumors. Br J Cancer 1990; 62: 925–931
   PubMed Web of Science ®Google Scholar
• Raleigh J A, Zeman E M, Rathman M, et al. Development of an ELISA for the detection of 2-nitoimidazole hypoxia markers bound to tumor tissue. Int J Radiat Oncol Biol Phys 1992; 22: 403–405
   PubMed Web of Science ®Google Scholar
• Sostman H D, Prescott D M, Dewhirst M W, et al. MR imaging and spectroscopy for prognostic evaluation in soft-tissue sarcomas. Radiology 1994; 190: 269–275
   PubMed Web of Science ®Google Scholar
• Prescott D M, Charles H C, Sostman H D, et al. Therapy monitoring in human and canine soft tissue sarcomas using magnetic resonance imaging and spectroscopy. Int J Radiat Oncol Biol Phys 1994; 28: 415–423
   PubMed Web of Science ®Google Scholar
• Brodey R. The use of naturally occurring caner in domestic animals for research into human cancer: general considerations and a review of canine skel et al osteosarcomas. Yale J Biol Med 1979; 52: 345–362
   PubMed Web of Science ®Google Scholar
• Withrow S, Powers B, Straw R, et al. Comparative aspects of osteosarcoma. Dog versus man. Clin Orthop 1991; 270: 159–168
   PubMedGoogle Scholar
• MacEwen E G. Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Rev 1990; 9: 125–136
   PubMed Web of Science ®Google Scholar
• Misdorp W, Hart A. Some prognostic and epidemiologic factors in canine osteosarcoma. J Natl Cancer Inst 1979; 62: 537–545
   PubMed Web of Science ®Google Scholar
• Johnson A, Couto C, Weghorst C. Mutations of the p53 tumor suppresssor gene in spontaneously occurring osteosarcomas of the dog. Carcinogenesis 1998; 19: 213–217
   PubMed Web of Science ®Google Scholar
• Brodey R, Riser W. Canine osteosarcoma: a clinicopathologic study of 194 cases. Clin Orthop 1969; 62: 54–64
   PubMedGoogle Scholar
• Spodnick G, Berg R, Rand W, et al. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978–1988). J Am Vet Med Assoc 1992; 200: 995–999
   PubMed Web of Science ®Google Scholar
• Straw R. Tumors of the skel etal system. Small Animal Clinical Oncology, 2nd ed., S J Winthrow, E G MacEwen. W.B. Saunders, Philadelphia 1996; 287–315
   Google Scholar
• Fidler I J, Sone S, Fogler W E, et al. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci USA 1981; 78: 1680–1684
   PubMed Web of Science ®Google Scholar
• Fidler I, Sone S, Fogler W E, et al. Efficacy of liposomes containing a lipophilic muramyl dipeptide for activating the tumoricidal properties of alveolar macrophages in vivo. J Biol Response Mod 1982; 1: 43–55
   Google Scholar
• Fidler I. Therapy of cancer metastasis by systemic activation of macrophages. Adv Pharmacol 1994; 30: 271–326
   PubMedGoogle Scholar
• Smith B, Kurzman I, Schultz K, et al. Muramyl peptides augment the in vitro and in vivo cytostatic activity of canine plasticadherent mononuclear cells against canine osteosarcoma cells. Cancer Biother 1993; 137–144
   PubMedGoogle Scholar
• Shi F, MacEwen E G, Kurzman I D. In vitro and in vivo effect of doxorubicin combined with liposome-encapsulated muramyle tripeptide on canine monocyte activation. Cancer Res 1993; 53: 3986–3991
   PubMed Web of Science ®Google Scholar
• Shi F, Kurzman I D, MacEwen E G. In vitro and in vivo production of interleukin-6 induced by muramyl peptides and lipopolysaccharide in normal dogs. Cancer Biother 1995; 10: 317–325
   PubMedGoogle Scholar
• Kurzman I, Shi F, MacEwen E G. In vitro and in vivo canine mononuclear cell production of tumor cell production of tumor necrosis factor induced by muramyl peptides and lipopolysaccharide. Vet Immunol Immunopath 1993; 38: 45–56
   PubMed Web of Science ®Google Scholar
• Kleinerman E, Erickson K L, Schroit A J, et al. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. Cancer Res 1983; 43: 2010–2014
   PubMed Web of Science ®Google Scholar
• Kleinerman E, Schroit A J, Folger W E, et al. Tumoricidal activity of human monocytes activated in vitro by free and liposomeencapsulated human lymphokines. J Clin Invest 1983; 72: 1–12
   PubMedGoogle Scholar
• Kleinerman E, Jia S F, Griffin J, et al. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol 1992; 10: 1310–1316
   PubMed Web of Science ®Google Scholar
• Kleinerman E, Raymond A K, Bucana C D, et al. Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer immunol Immunother 1992; 34: 211–220
   PubMed Web of Science ®Google Scholar
• Kleinerman E, Gano J B, Johnston D. A., et al. efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol 1995; 18: 93–99
   PubMed Web of Science ®Google Scholar
• MacEwen E, Kurzman I. D., Rosenthal R C, et al. Therapy for osteosarcoma in dogs with intravenous injection of liposomeencapsulated muramyl tripeptide. J Natl Cancer Inst 1989; 81: 935–938
   PubMed Web of Science ®Google Scholar
• Kurzman I, MacEwen E, Rosental R, et al. Ajuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. J Clin Cancer Res 1995; 1: 1595–1601
   Web of Science ®Google Scholar
• Hammer A S, Couto C., Filippi G. J., et al. Efficacy and toxicity of VAC chemotherapy in dogs with hemangiosarcoma. J Vet Intern Med 1991; 5: 160–166
   PubMed Web of Science ®Google Scholar
• Sorenmo K U, Jeglum K., Helt A. SC. Chemotherapy of canine hemangiosarcoma with doxorubicin and cyclophosphamide. J Vet Intern Med 1993; 7: 370–376
   PubMed Web of Science ®Google Scholar
• Brown N O, Patnaik A K, MacEwen E G. Canine hemangiosarcoma: retrospective analysis of 104 cases. Am Vet Med Assoc 1981; 186: 56–58
   Google Scholar
• Madewell B R, Griffey S M, Munn R J. Ultrastructure of canine vasoformative tumors. J Vase Res 1992; 29: 50–55
   PubMed Web of Science ®Google Scholar
• Spangler W. L., Culbertson M R. Prevalence, type, and importance of splenic diseases in dogs: 1,480 cases (1985–1989). J Am Vet Med Assoc 1992; 200: 829–834
   PubMed Web of Science ®Google Scholar
• Holt D, Van Winkle T, Schelling C, et al. Correlation between thoracic radiographs and postmortem findings in dogs with hemangiosarcoma: 77 cases (1984–1989). J Am Vet Med Assoc 1992; 200: 1535–1539
   PubMed Web of Science ®Google Scholar
• Prymak C, McKee L J, Goldschmidt M. H., et al. Epidemiologic. clinical, pathologic, and prognostic characteristics of splenic hemangiosarcoma and splenic hematoma in dogs: 217 cases (1985). J Am Vet Med Assoc 1988; 193: 706–712
   PubMed Web of Science ®Google Scholar
• Vail D., Mac M., Ewen E G, Kurzman I D, et al. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE) immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial. Clin Cancer Res 1995; I: 1165–1170
   Google Scholar
• Schneider Dorn R., Taylor C. D. Factors influencing canine mammary cancer development and postsurgical survival. J Natl Cancer Inst 1969; 43: 1249–1261
   PubMed Web of Science ®Google Scholar
• MacEwen E, Patnaik A, Harvey H, et al. Estrogen receptors in canine mammary tumors. Cancer Res 1982; 42: 2255–2259
   PubMed Web of Science ®Google Scholar
• Sartin E, Kwapien S., Barnes R., et al. Estrogen and progesterone receptor status of mammary carcinomas and correlation with outcome. Am J Vet Res 1992; 53: 2196–2200
   PubMed Web of Science ®Google Scholar
• Yamagami T, Kobayashi T, Takahashi K., et al. Influence of ovariectomy at the time of mastectomy on the prognosis for canine malignant mammary tumors. J Small Animal Pract 1996; 37: 462–464
   PubMed Web of Science ®Google Scholar
• Morris J, Dobson J, Bostock D. Use of tamoxifen in the control of mammary neoplasia. Vet Rec 1993; 133: 539–542
   PubMed Web of Science ®Google Scholar
• Ahern T, Bird C., Bird A., et al. Expression of the oncogene cerbB-2 in canine mammary cancers and tumor-derived cell lines. Am J Vet Res 1996; 57: 693–696
   PubMed Web of Science ®Google Scholar
• Gilbertson S. Canine mammary epithelial neoplasms: biological implications of morphologic characteristics assessed in 232 dogs. Vet Path 1983; 20: 127
   PubMed Web of Science ®Google Scholar
• Allen Mahaffey S. E. Canine mammary neoplasia: prognostic indicators and response to surgical therapy. J Am Anim Hosp Assoc 1989; 25: 540
   Web of Science ®Google Scholar
• Kurzman I, Gilbertson S. Prognostic factors in cancine mammary tumors. Semin Vet Med Surg 1986; 1: 25–32
   PubMedGoogle Scholar
• Hahn K, Richardson R, Knapp D. Canine malignant mammary neoplasia: biologic behavior, diagnosis, and treatment alternatives. J Am Anim Hosp Assoc 1992; 28: 251
   Web of Science ®Google Scholar
• Ogilvie G. Phase II evaluation of doxorubicin for treatment of various canine neoplasms. J Am Vet Med Assoc 1989; 195: 1580
   PubMed Web of Science ®Google Scholar
• Parodi A, Misdorp W, Mialot J, et al. Intratumoral BCG and Corynebacterium parvum therapy of canine mammary tumors before radical mastectomy. Cancer Immuno Immunother 1983; 15: 172–177
   PubMed Web of Science ®Google Scholar
• Teske E, Rutteman G, Ingh T, et al. Liposome-encapsulated muramyl tripeptide phosphatidyl-ethanolamine (L-MTP-PE): a randomized clinical trial in dogs with mammary cancer. Anticancer Res 1998; 18: 1015–1020
   PubMed Web of Science ®Google Scholar
• Bostock D, Gorman N. Intravenous BCG therapy os mammary carcinoma in bitches after surgical excision of the primary tumor. Eur J Cancer 1978; 14: 879–883
   PubMed Web of Science ®Google Scholar
• MacEwen E, Harvey H, Patnaik A, et al. Evaluation of effects of levamisole and surgery on canine mammary cancer. J Biol RespModif 1985; 4: 418–426
   Google Scholar
• Rutteman G, Blankenstein M, Minke J, et al. Steriod receptors in mammary tumours in the cat. Acta Endocrinol 1991; 125: 32–37
   PubMedGoogle Scholar
• Weijer K, Hart A. Prognostic factors for feline mammary tumors. J Natl Cancer Inst 1983; 70: 709–710
   PubMed Web of Science ®Google Scholar
• MacEwen E, Hayes A, Harvey H, et al. prognostic factors for feline mammary tumors. J Am Vet Med Assoc 1984; 185: 201–204
   PubMed Web of Science ®Google Scholar
• Mauldin G, Matus R, Patnaik A, et al. Efficacy and toxicity of doxorubicin and cyclophasphamide used in the treatment of selected malignant tumors in 23 cats. J Vet Intern Med 1988; 23: 60–65
   Google Scholar
• MacEwen E, Hayes A, Mooney S, et al. Evaluation of effect of levamisole on feline mammary cancer. J Biol Resp Modif 1984; 5: 541–546
   Google Scholar
• Fox L, MacEwen E, Kurzman I, et al. Liposome-encapsulated MTP-PE for the treatment of feline mammary adenocarcinoma. A multicenter randomized double-blind study. Cancer Biother 1995; 10: 125–130
   PubMedGoogle Scholar
• Bostock D. Prognosis after surgical excision of canine melanoma. Vet Pathol 1979; 32: 32–40
   Google Scholar
• Harvey H J, MacEwen E G, Braun D, et al. Prognostic criteria for dogs with oral melanoma. JAVMA 1981; 178: 580–582
   PubMed Web of Science ®Google Scholar
• Salisbury S, Lantz G C. Long-term results of partial mandibulectomy for treatment of oral melanoma in 30 dogs. J Am Anim Hosp Assoc 1988; 24: 285–294
   Web of Science ®Google Scholar
• Bateman K E, Catton P A, Pennock P W, et al. 0–7–21 Radiation therapy for the treatment of canine oral melanoma. J Vet Intern Med 1994; 8: 267–272
   PubMed Web of Science ®Google Scholar
• MacEwen E, Patnaik A K, Harvey H J, et al. Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum. Cancer Invest 1986; 4: 397–402
   PubMed Web of Science ®Google Scholar
• Hahn K, DeNicola D, Richardson R, et al. Canine oral malignant melanoma: prognostic utility of an alternative staging system. J Small Anim Pract 1994; 35: 251–256
   Web of Science ®Google Scholar
• MacEwen E, Kurzman I, Vail D, et al. Adjuvant therapy for melanoma in dogs: results of randomized clincial trials using surgery, liposmone-encapsulated muramyl tripeptide, and GM-CSF. Clin Cancer Res 1999; 5: 4249–4258
   PubMed Web of Science ®Google Scholar
• Hahn K L. B, Adams W, et al. Naturally occurring tumors in dogs as comparative models for cancer therapy research. In Vivo 1994; 8: 133–144
   PubMedGoogle Scholar
• Liebes L, Walsh C M, Chachaua A, et al. Modulation of monocyte functions by muramyl tripeptide phosphatidlyethanolamime in a phase II study in patients with metastatic melanoma. J Natl Cancer Inst 1992; 84: 694–699
   PubMed Web of Science ®Google Scholar
• Fujimaki W, Itoh K, An T, et al. Cytokine production and immune cell activation in melanoma patients treated with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Biother 1993; 8: 307–318
   PubMedGoogle Scholar
• Hogge G, Burkholder J, Gulp J, et al. Development of human granulocyte-macrophage-colony stimulating factor-transfected tumor cell vaccines for the treatment of spontaneous canine cancer. Hum Gene Ther 1998; 9: 1851–1861
   PubMed Web of Science ®Google Scholar
• Dow S, Elmslie R E, Willson A P, et al. In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J Clin Invest 1998; 101: 2406–2414
   PubMed Web of Science ®Google Scholar